Tuesday, September 11, 2012 2:45:36 PM
Why I don't worry about 3 year old news
Updated Elite's partners - My money is betting on them
I am going to bet that all these partners that have put all these products in Elite's hands know what they are doing.
HK Pharma - Elite is doing all the work to develop an NDA for an undisclosed Hong Kong Pharma company. This is a new drug approved overseas to be marketed here in the USA, manufactured by Elite
Actavis - 2 product transfers and one NDA in development, all for Mikah designee as noted below
http://www.actavis.us/en/default.htm
Mikah Pharma - designee of Actavis, VP at Actavis consultant to Epic - Product pending now from recent completion of FDA inspections, one more product transfer pending and development of an NDA!!
"Mikah Pharma has contracted Elite Pharmaceuticals to develop and manufacture our top leading products.
Elite will develop MIK001’s formulation, analytical methodology, and manufacture, test and release the clinical supplies necessary for our clinical trials and NDA approval"
http://mikahpharma.com/
Epic Pharma and CTO of Elite, half of BOD of Elite, can own ~50% of Elite. Making 8 products with Elite - One pending now
http://www.epic-pharma.com/
Hi-tech Pharmacal - HITK - Lodrane line, generic of 100m branded product
http://www.hitechpharm.com/
ECR - Lodrane
http://www.ecrpharma.com/
TAGI Pharma - Elite owned ANDAs, also handles Roxane and Epic products. Review the wholesalers being used!! 2 Products pending now from recent completion of FDA inspections.
http://www.tagipharma.com/products.html
The Pharma-Network - Ascend Labs - Methadone
http://www.ascendlaboratories.com/
Novel Labs - Elite owns 10%
"Novel has an aggressive pipeline forecasting 10 to 12 ANDA approvals and product launches per year. In its first year alone, Novel filed 8 ANDAs with the USFDA. Currently, Novel has identified over 50 drug products which are in various stages of development to be commercialized in the coming years. As a tenacious first-to-file generic comapany, Novel is continuously pursuing first-to-file & first-to-market opportunities and to date has been awarded 5 first-to-files while awaiting 2 more.
Novel currently has over 20 ANDAs with the USFDA. 5 of those applications have been approved and 3 have received tentative approvals. To supplement its considerable in-house R&D capabilities, Novel has acquired 8 additional ANDAs from other firms for manufacturing and marketing."
http://www.novellabs.net/
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=79145196
Socius - withdrawn financing deal pending new deal with Socius or other options as noted on CCs
New Partners - Elite has other products in the pipeline including another opioid pending FDA approval but no announced marketing partner. Should we add the co-inventors on these new patents now too?
Updated Elite's partners - My money is betting on them
I am going to bet that all these partners that have put all these products in Elite's hands know what they are doing.
HK Pharma - Elite is doing all the work to develop an NDA for an undisclosed Hong Kong Pharma company. This is a new drug approved overseas to be marketed here in the USA, manufactured by Elite
Actavis - 2 product transfers and one NDA in development, all for Mikah designee as noted below
http://www.actavis.us/en/default.htm
Mikah Pharma - designee of Actavis, VP at Actavis consultant to Epic - Product pending now from recent completion of FDA inspections, one more product transfer pending and development of an NDA!!
"Mikah Pharma has contracted Elite Pharmaceuticals to develop and manufacture our top leading products.
Elite will develop MIK001’s formulation, analytical methodology, and manufacture, test and release the clinical supplies necessary for our clinical trials and NDA approval"
http://mikahpharma.com/
Epic Pharma and CTO of Elite, half of BOD of Elite, can own ~50% of Elite. Making 8 products with Elite - One pending now
http://www.epic-pharma.com/
Hi-tech Pharmacal - HITK - Lodrane line, generic of 100m branded product
http://www.hitechpharm.com/
ECR - Lodrane
http://www.ecrpharma.com/
TAGI Pharma - Elite owned ANDAs, also handles Roxane and Epic products. Review the wholesalers being used!! 2 Products pending now from recent completion of FDA inspections.
http://www.tagipharma.com/products.html
The Pharma-Network - Ascend Labs - Methadone
http://www.ascendlaboratories.com/
Novel Labs - Elite owns 10%
"Novel has an aggressive pipeline forecasting 10 to 12 ANDA approvals and product launches per year. In its first year alone, Novel filed 8 ANDAs with the USFDA. Currently, Novel has identified over 50 drug products which are in various stages of development to be commercialized in the coming years. As a tenacious first-to-file generic comapany, Novel is continuously pursuing first-to-file & first-to-market opportunities and to date has been awarded 5 first-to-files while awaiting 2 more.
Novel currently has over 20 ANDAs with the USFDA. 5 of those applications have been approved and 3 have received tentative approvals. To supplement its considerable in-house R&D capabilities, Novel has acquired 8 additional ANDAs from other firms for manufacturing and marketing."
http://www.novellabs.net/
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=79145196
Socius - withdrawn financing deal pending new deal with Socius or other options as noted on CCs
New Partners - Elite has other products in the pipeline including another opioid pending FDA approval but no announced marketing partner. Should we add the co-inventors on these new patents now too?
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
